Parabilis Medicines Q2 Loss Narrows; Shares Rise Pre-Bell

MT Newswires Live

Aug 13

Parabilis Medicines (PBLS) reported a Q2 loss Thursday $2.32 per diluted share, compared a loss of $22.28 a year earlier.

Analysts from FactSet expected a loss of $0.36.

Collaboration revenue for the quarter ended June 30 was $148,000. The company did not report any revenue a year ago.

As of June 30, the company has cash, cash equivalents and marketable securities of $1.1 billion, which it said are expected to fund its operations into 2030.

Shares of the company were up over 6% in Thursday's premarket activity.

Price: 39.99, Change: +2.58, Percent Change: +6.90

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2659715159"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2659715159\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2659715159?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-13 19:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2659715159","market":"us","top_or_hot":-1,"title":"Parabilis Medicines Q2 Loss Narrows; Shares Rise Pre-Bell","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PBLS\">Parabilis Medicines</a> (PBLS) reported a Q2 loss Thursday $2.32 per diluted share, compared a loss of $22.28 a year earlier.</p><p>Analysts from FactSet expected a loss of $0.36.</p><p>Collaboration revenue for the quarter ended June 30 was $148,000. The company did not report any revenue a year ago.</p><p>As of June 30, the company has cash, cash equivalents and marketable securities of $1.1 billion, which it said are expected to fund its operations into 2030.</p><p>Shares of the company were up over 6% in Thursday's premarket activity.</p><p>Price: 39.99, Change: +2.58, Percent Change: +6.90</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Parabilis Medicines Q2 Loss Narrows; Shares Rise Pre-Bell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nParabilis Medicines Q2 Loss Narrows; Shares Rise Pre-Bell\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-13 19:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PBLS\">Parabilis Medicines</a> (PBLS) reported a Q2 loss Thursday $2.32 per diluted share, compared a loss of $22.28 a year earlier.</p><p>Analysts from FactSet expected a loss of $0.36.</p><p>Collaboration revenue for the quarter ended June 30 was $148,000. The company did not report any revenue a year ago.</p><p>As of June 30, the company has cash, cash equivalents and marketable securities of $1.1 billion, which it said are expected to fund its operations into 2030.</p><p>Shares of the company were up over 6% in Thursday's premarket activity.</p><p>Price: 39.99, Change: +2.58, Percent Change: +6.90</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2659715159","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2659715159","pubTimestamp":1786621592,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Parabilis Medicines  reported a Q2 loss Thursday $2.32 per diluted share, compared a loss of $22.28 a year earlier.Analysts from FactSet expected a loss of $0.36.Collaboration revenue for the quarter ended June 30 was $148,000. The company did not report any revenue a year ago.As of June 30, the company has cash, cash equivalents and marketable securities of $1.1 billion, which it said are expected to fund its operations into 2030.Shares of the company were up over 6% in Thursday's premarket activity.Price: 39.99, Change: +2.58, Percent Change: +6.90","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PBLS":"Parabilis Medicines"},"translate_title":"Parabilis Medicines Q2亏损收窄；盘前股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PBLS":1.5},"content_text":"Parabilis Medicines (PBLS) reported a Q2 loss Thursday $2.32 per diluted share, compared a loss of $22.28 a year earlier.Analysts from FactSet expected a loss of $0.36.Collaboration revenue for the quarter ended June 30 was $148,000. The company did not report any revenue a year ago.As of June 30, the company has cash, cash equivalents and marketable securities of $1.1 billion, which it said are expected to fund its operations into 2030.Shares of the company were up over 6% in Thursday's premarket activity.Price: 39.99, Change: +2.58, Percent Change: +6.90","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}